H.C. Wainwright analyst Andrew Fein raised the firm’s price target on United Therapeutics (UTHR) to $525 from $500 and keeps a Buy rating on the shares following the Q3 report. The firm cites Tyvaso revenue growth and the “strong” early launch of Yutrepia for the target boost.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics price target raised to $447 from $435 at Morgan Stanley
- United Therapeutics: Hold Rating Amid Optimistic Partnership Prospects and Adjusted Revenue Goals
- United Therapeutics Reports Record Q3 2025 Results
- United Therapeutics Corp’s Earnings Call Highlights Growth and Innovation
- Strong Growth Potential and Strategic Initiatives Drive Buy Rating for United Therapeutics